Metformin Accord

Metformin Hydrochloride, the active ingredient in Metformin Accord, is a Biguanide presented as a tablet for oral use. It reduces hepatic glucose production and enhances peripheral insulin sensitivity, providing glycaemic control for adults with type 2 diabetes mellitus.

GNH USA supplies Metformin Accord as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies and clinics worldwide through regulated manufacturing and quality‑assured distribution channels. All batches comply with EU pharmacopoeial specifications and are subject to rigorous stability testing.

Metformin Accord, a biguanide antidiabetic, acts on glucose metabolism to improve glycaemic control.

- Type 2 diabetes mellitus: lowers blood glucose levels and helps maintain target HbA1c values in adult patients.

Metformin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, and diarrhea. - Metallic taste in the mouth. - Decreased appetite.

Serious or Rare Side Effects: - Lactic acidosis: a rare but potentially fatal metabolic complication. - Severe vitamin B12 deficiency leading to neuropathy. - Hepatotoxicity: abnormal liver function tests in rare cases.

When prescribing Metformin Accord, clinicians should consider several safety measures.

- Renal function assessment: evaluate eGFR before initiation and periodically. - Hepatic function monitoring: avoid use in patients with significant liver disease. - Contraindicated in severe renal impairment: do not use if eGFR <30 mL/min/1.73 m². - Alcohol consumption: limit intake to reduce risk of lactic acidosis. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Metformin Accord can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Iodinated contrast media: avoid concurrent use due to risk of acute renal failure. - Cimetidine: may increase metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): may affect renal clearance of metformin. - Corticosteroids: can raise blood glucose, necessitating dose adjustment. - Beta‑blockers: may mask symptoms of hypoglycaemia.